How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology

Abstract

Efforts are underway to transform regulatory toxicology and chemical safety assessment from a largely empirical science based on direct observation of apical toxicity outcomes in whole organism toxicity tests to a predictive one in which outcomes and risk are inferred from accumulated mechanistic understanding. The adverse outcome pathway (AOP) framework provides a systematic approach for organizing knowledge that may support such inference. Likewise, computational models of biological systems at various scales provide another means and platform to integrate current biological understanding to facilitate inference and extrapolation. We argue that the systematic organization of knowledge into AOP frameworks can inform and help direct the design and development of computational prediction models that can further enhance the utility of mechanistic and in silico data for chemical safety assessment. This concept was explored as part of a workshop on AOP-Informed Predictive Modeling Approaches for Regulatory Toxicology held September 24–25, 2015. Examples of AOP-informed model development and its application to the assessment of chemicals for skin sensitization and multiple modes of endocrine disruption are provided. The role of problem formulation, not only as a critical phase of risk assessment, but also as guide for both AOP and complementary model development is described. Finally, a proposal for actively engaging the modeling community in AOP-informed computational model development is made. The contents serve as a vision for how AOPs can be leveraged to facilitate development of computational prediction models needed to support the next generation of chemical safety assessment.

Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity

“…Strategies such as the Tox21 Initiative (40) are designed to improve the predictability of adverse outcomes and to reduce the use of animals in systems-level analysis in preclinical pharmacology and toxicology. Recent efforts have focused on developing in vitro models, such as in silico PK/PD modeling, high-throughput screening for nuclear receptor signaling and stress pathway assays, and adverse outcome pathway-based toxicity modeling (41). Finally, to our knowledge, this is the first example of microfluidically linked human organs-on-chips being applied to this type of investigation.…”

In vitro label‐free screening of chemotherapeutic drugs using Raman microspectroscopy: Towards a new paradigm of spectralomics

“…An assessment of the action and efficacy of, for example, a chemotherapeutic agent, according to a single endpoint is therefore extremely limited. Computational modelling approaches to predictive toxicity, such as that of adverse outcome pathways , have sought to deconvolute the action of exogenous agents, in terms of the molecular initiating event (MIE) and the subsequent cascade of key event (KE) that reflect the causal progression from the initial perturbation of the system towards the adverse outcome. In the context of the action of chemotherapeutic drugs in vitro, the MIE can be considered the chemical interaction of the drug, for example, in the cell nucleus, while the subsequent cascade of events can determine the efficacy of a drug action.…”

Rethinking developmental toxicity testing: Evolution or revolution?

“…Although a standard approach to considering adverse outcome pathways assumes a linear, unidirectional scheme such as shown in Figure , biological systems are more likely to be complex, and adverse outcome pathways are interconnected in multiple ways and directions (Browne, Noyes, Casey, & Dix, ; Wittewehr et al, ; Figure ). If we envision all possible interconnected pathways involved in development, we would get a very busy diagram.…”